| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Urology and Therapeutics Program, Department of Urology, Box 422 University of Virginia Health Sciences Center, Charlottesville, Virginia 22908 [S-C. K., J. C., C. K., A. G., T. S., R. A. S., L. W. K. C.], and Department of Molecular Genetics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030 [G. K.]
Osteocalcin (OC), a noncollagenous bone matrix protein, is expressed in high levels by osteoblasts. To determine whether the OC promoter mediates cell-specific gene expression in cells of osteoblast lineage, we constructed a recombinant adenovirus, Ad-OC-TK, which contains the OC promoter that drives the expression of herpes simplex virus thymidine kinase (TK). We tested the expression of TK by this virus in osteoblast cell lines as well as in non-osteoblastic cell lines by assessing the enzyme activity of TK in vitro. Whereas the OC promoter failed to drive the expression of the TK gene in several non-osteoblastic cell lines such as WH, a human bladder transitional carcinoma, and NIH 3T3, an embryonic mouse fibroblast cell line, the OC promoter mediated high levels of expression in osteoblast cell lines including murine ROS and human MG-63 cells. The addition of acyclovir (ACV), a pro-drug for the inhibition of cell proliferation, resulted in the induction of osteoblast-specific cell death in vitro. Intratumoral injection of Ad-OC-TK into murine ROS osteosarcoma abolished tumor growth in a host treated with subsequent i.p. ACV injection in vivo. The Ad-OC-TK virus plus ACV treatment appears to be highly selective in blocking the growth of both murine and human osteosarcoma cell lines in vitro and murine osteosarcoma in vivo.
1 These authors contributed equally to this study.
2 To whom requests for reprints should be addressed, at Department of Urology, Molecular Urology and Therapeutics Program, The University of Virginia Health Science Center, Box 422, Charlottesville, VA 22908.
Received 7/29/96. Accepted 8/28/96.
This article has been cited by other articles:
|
|
 |
|
  X. Li, Y.-P. Zhang, H.-S. Kim, K.-H. Bae, K. M. Stantz, S.-J. Lee, C. Jung, J. A. Jimenez, T. A. Gardner, M.-H. Jeng, et al. Gene Therapy for Prostate Cancer by Controlling Adenovirus E1a and E4 Gene Expression with PSES Enhancer Cancer Res., March 1, 2005; 65(5): 1941 - 1951. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Marina, M. Gebhardt, L. Teot, and R. Gorlick Biology and Therapeutic Advances for Pediatric Osteosarcoma Oncologist, July 1, 2004; 9(4): 422 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Witlox, V. W. van Beusechem, B. Molenaar, H. Bras, G. R. Schaap, R. Alemany, D. T. Curiel, H. M. Pinedo, P. I. J. M. Wuisman, and W. R. Gerritsen Conditionally Replicative Adenovirus with Tropism Expanded towards Integrins Inhibits Osteosarcoma Tumor Growth in Vitro and in Vivo Clin. Cancer Res., January 1, 2004; 10(1): 61 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Takeda, H. Inaba, M. Yamazaki, S. Kyo, T. Miyamoto, S. Suzuki, T. Ehara, T. Kakizawa, M. Hara, L. J. DeGroot, et al. Tumor-Specific Gene Therapy for Undifferentiated Thyroid Carcinoma Utilizing the Telomerase Reverse Transcriptase Promoter J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3531 - 3538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Oosterhoff, M. A. Witlox, V. W. van Beusechem, H. J. Haisma, G. R. Schaap, J. Bras, F. A. Kruyt, B. Molenaar, E. Boven, P. I. J. M. Wuisman, et al. Gene-directed Enzyme Prodrug Therapy for Osteosarcoma: Sensitization to CPT-11 in Vitro and in Vivo by Adenoviral Delivery of a Gene Encoding Secreted Carboxylesterase-2 Mol. Cancer Ther., August 1, 2003; 2(8): 765 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zhang, F. H. Straus, and L. J. DeGroot Cell-Specific Viral Gene Therapy of a Hurthle Cell Tumor J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1407 - 1414. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Matsubara, Y. Wada, T. A. Gardner, M. Egawa, M.-S. Park, C.-L. Hsieh, H. E. Zhau, C. Kao, S. Kamidono, J. Y. Gillenwater, et al. A Conditional Replication-competent Adenoviral Vector, Ad-OC-E1a, to Cotarget Prostate Cancer and Bone Stroma in an Experimental Model of Androgen-independent Prostate Cancer Bone Metastasis Cancer Res., August 1, 2001; 61(16): 6012 - 6019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Boskey Musculoskeletal Disorders and Orthopedic Conditions JAMA, February 7, 2001; 285(5): 619 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Minemura, T. Takeda, K. Minemura, T. Nagasawa, R. Zhang, R. Leopardi, and L. J. DeGroot Cell-Specific Induction of Sensitivity to Ganciclovir in Medullary Thyroid Carcinoma Cells by Adenovirus-Mediated Gene Transfer of Herpes Simplex Virus Thymidine Kinase Endocrinology, May 1, 2000; 141(5): 1814 - 1822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Hou, Q. Nguyen, B. Frenkel, S. K. Nilsson, M. Milne, A. J. van Wijnen, J. L. Stein, P. Quesenberry, J. B. Lian, and G. S. Stein Osteoblast-specific gene expression after transplantation of marrow cells: Implications for skeletal gene therapy PNAS, June 22, 1999; 96(13): 7294 - 7299. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
